|

Efficacy of Early Rhythm Control in AF With TR Patients

RECRUITINGSponsored by Samsung Medical Center
Actively Recruiting
SponsorSamsung Medical Center
Started2026-02-18
Est. completion2027-02-28
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07607093

Summary

Atrial fibrillation is frequently accompanied by tricuspid regurgitation and may contribute to right atrial and tricuspid annular remodeling, leading to progression of tricuspid regurgitation and adverse clinical outcomes. However, whether early rhythm control improves prognosis in patients with atrial fibrillation and tricuspid regurgitation remains unclear. This study will compare early rhythm control with usual care in these patients, using a composite outcome of cardiac death, heart failure admission, stroke, and tricuspid valve surgery.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Patients with concomitant atrial fibrillation and tricuspid regurgitation.

Exclusion Criteria:

* Patients with a history of valvular surgery
* Patients with congenital heart disease
* Patients with primary pulmonary hypertension
* Patients with CIED implantation prior to the diagnosis of tricuspid regurgitation
* Patients diagnosed with TR only after the initiation of rhythm control therapy for AF

Conditions3

Atrial Fibrillation (AF)Heart DiseaseTricuspid Regurgitation (TR)

Interventions1

Anti-arrhythmic drugs for rhythm control

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.